• Mineralys IPO Lands $192M for Blood Pressure Trials and Chance to Challenge AstraZeneca

    1 month ago - By MedCity News

    Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.
    Read more ...